Precision BioSciences to Report Second Quarter Results on August 1, 2024
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced that it will release its second quarter 2024 financial results and provide a business update on August 1, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies. This upcoming report will offer investors and analysts insights into Precision BioSciences' financial performance and operational progress for the quarter ending June 30, 2024.
Precision BioSciences (Nasdaq: DTIL), un'azienda avanzata nel settore dell'editing genetico, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 e fornirà un aggiornamento aziendale il 1 agosto 2024. L'azienda utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genetico in vivo. Questo prossimo rapporto offrirà agli investitori e agli analisti informazioni sulle prestazioni finanziarie e sui progressi operativi di Precision BioSciences per il trimestre conclusosi il 30 giugno 2024.
Precision BioSciences (Nasdaq: DTIL), una empresa avanzada en edición genética, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y proporcionará una actualización comercial el 1 de agosto de 2024. La compañía utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo. Este próximo informe ofrecerá a los inversores y analistas información sobre el rendimiento financiero y el progreso operativo de Precision BioSciences durante el trimestre que finaliza el 30 de junio de 2024.
프리시전 바이오사이언스(나스닥: DTIL), 첨단 유전자 편집 회사, 는 2024년 2분기 재무 결과를 발표하고 2024년 8월 1일에 사업 업데이트를 제공할 것이라고 발표했습니다. 이 회사는 독자적인 ARCUS® 플랫폼을 활용하여 체내 유전자 편집 치료법을 개발합니다. 이번 보고서는 2024년 6월 30일로 종료되는 분기 동안 프리시전 바이오사이언스의 재무 성과 및 운영 진행 상황에 대한 통찰력을 투자자 및 분석가에게 제공할 것입니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise avancée dans l'édition génétique, a annoncé qu'elle publiera ses résultats financiers du second trimestre 2024 et fournira une mise à jour commerciale le 1er août 2024. L'entreprise utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génétique in vivo. Ce prochain rapport offrira aux investisseurs et aux analystes des informations sur la performance financière et les progrès opérationnels de Precision BioSciences pour le trimestre se terminant le 30 juin 2024.
Precision BioSciences (Nasdaq: DTIL), ein fortschrittliches Unternehmen für Gen-Editing, hat angekündigt, dass es am 1. August 2024 seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen und ein Unternehmensupdate bereitstellen wird. Das Unternehmen nutzt seine proprietäre ARCUS®-Plattform, um in vivo Gen-Editing-Therapien zu entwickeln. Dieser kommende Bericht wird Investoren und Analysten Einblicke in die finanzielle Leistung und den operativen Fortschritt von Precision BioSciences für das Ende des Quartals am 30. Juni 2024 geben.
- None.
- None.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729870773/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When will Precision BioSciences (DTIL) report its Q2 2024 earnings?
What is Precision BioSciences' (DTIL) primary technology platform?
What type of company is Precision BioSciences (DTIL)?
What information will Precision BioSciences (DTIL) provide on August 1, 2024?
